Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy | Zendy

JaeSang Ko | Zendy; Ji-Young Kim | Zendy; Eun Jig Lee | Zendy; Jin Sook Yoon | Zendy

Open Access

Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy

Author(s) -

JaeSang Ko,

Ji-Young Kim,

Eun Jig Lee,

Jin Sook Yoon

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-24509

Subject(s) - idelalisib , pi3k/akt/mtor pathway , foxo1 , protein kinase b , adipogenesis , chemistry , medicine , endocrinology , cancer research , phosphorylation , signal transduction , biology , in vitro , biochemistry , ibrutinib , chronic lymphocytic leukemia , leukemia

Emerging evidence indicates that the phosphatidylinositol 3-kinase (PI3K)-AKT pathway is involved in the pathogenesis of Graves' orbitopathy (GO). In this study, the therapeutic effects of idelalisib, a selective PI3Kδ inhibitor, on adipogenesis were evaluated in GO orbital fibroblasts in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research